|
Volumn 183, Issue 5, 2005, Pages 275-276
|
Letter to the Editor (multiple letters) [2]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
FLUOXETINE;
PLACEBO;
SEROTONIN UPTAKE INHIBITOR;
TRICYCLIC ANTIDEPRESSANT AGENT;
BEHAVIOR THERAPY;
COGNITION;
DEPRESSION;
DIET;
DISEASE SEVERITY;
DRUG EFFICACY;
EXERCISE;
FREQUENCY ANALYSIS;
HUMAN;
LETTER;
LIFE EVENT;
PSYCHOPHARMACOTHERAPY;
PSYCHOTHERAPY;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
SUICIDE;
ADOLESCENT;
CHILD;
DRUG SCREENING;
MAJOR DEPRESSION;
TREATMENT OUTCOME;
NOTE;
UNITED KINGDOM;
UNITED STATES;
ADOLESCENT;
CHILD;
DEPRESSIVE DISORDER, MAJOR;
DRUG EVALUATION;
FLUOXETINE;
HUMANS;
SEROTONIN UPTAKE INHIBITORS;
SUICIDE;
TREATMENT OUTCOME;
GREAT BRITAIN;
RISK ASSESSMENT;
UNITED STATES;
|
EID: 24344453822
PISSN: 0025729X
EISSN: None
Source Type: Journal
DOI: 10.5694/j.1326-5377.2005.tb07039.x Document Type: Letter |
Times cited : (2)
|
References (0)
|